PYXS News and Press, Pyxis Oncology Inc. From 03/23/23

2023-03-23 17:01:12 ET Gainers: Pyxis Oncology ( PYXS ) +15% . CRISPR Therapeutics ( CRSP ) +11% . ADMA Biologics ( ADMA ) +6% . Harrow Health ( HROW ) +4% . Solid Power ( SLDP ) +5% . Losers: Scholastic ( SCHL ) -1...

2023-03-22 08:42:50 ET Pyxis Oncology ( NASDAQ: PYXS ) extended post-market gains on Wednesday, adding ~4% in early trading as Pfizer ( PFE ) raised its ownership in the cancer-focused biotech by more than a third ahead of its Q4 2022 financials. According to an SE...

2023-03-22 08:21:40 ET 89bio ( ETNB ) +50% on topline data for NASH candidate. GameStop ( GME ) +48% on Q4 earnings. Telesis Bio ( TBIO ) +17% on Q4 earnings. Pyxis Oncology ( PYXS ) +11% on Q4 earnings. Ollie's Bargain O...

2023-03-22 08:08:42 ET Pyxis Oncology press release ( NASDAQ: PYXS ): FY GAAP EPS of -$3.65 beats by $0.08 . As of December 31, 2022, Pyxis Oncology had cash and cash equivalents (including restricted cash) of $180.7 million, which is expected to fund operations into t...

Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 First subject dosed in Phase 1 trial of PYX-201; clinical sites being activated and patient screening underway in Phase 1 trial of PYX-106 Strong balance sheet with $180.7 million in cash (including res...

2023-03-16 08:17:07 ET Pyxis Oncology ( NASDAQ: PYXS ) said the first person was dosed in a phase 1 trial of PYX-201 for solid tumors. PYX-201 is a novel antibody-drug conjugate (ADC), which was licensed from Pfizer ( PFE ), targeting extradomain-B (EDB) of f...

Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 2024 CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics t...

CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, Pamela Connea...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about! Moving stocks are earnings reports, shareholder votes, public stoc...

FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate Phase 1 clinical trials of PYX-201 and PYX-106 will evaluate the safety and anti-tumor activity in patients with select solid tumors ...